Favipiravir for respiration disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 May 2020: Trial started, NCT04501783
  2. 6 Aug 2020: Trial registered, NCT04501783

The trials

NCT04501783: Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19

State
Completed
Phase
Phase 3
People
168 taking part
Started
20 May 2020
Primary completion
29 Jul 2020
Arms
TL-FVP-t (favipiravir) Treatment Arm
Results
None posted
  1. 20 May 2020: Trial started
  2. 4 Aug 2020: Trial completed
  3. 6 Aug 2020: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Avigan, Fabiflu, Favipiravir (3200 mg + 1200 mg), Favipiravir (3600 mg + 1600 mg), Favipiravir HU 200 mg hard capsules, Favipiravir tablets.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.